Advocacy

SDPA Statement on Topical Steroids

The Society of Dermatology Physician Assistants (SDPA) recognizes emerging evidence on potential adverse effects associated with prolonged topical corticosteroid use in managing chronic inflammatory dermatoses. These findings highlight the need for vigilant treatment planning to mitigate long-term risks. To prioritize patient safety and optimize outcomes, the SDPA advocates for routine assessment of cumulative steroid exposure as a cornerstone of patient care.

From the Hill: What the One Big Beautiful Bill Act Means for Dermatology PAs

Washington recently passed the wide-ranging One Big Beautiful Bill Act, a sweeping legislative package that touches everything from energy to tax reform.

Apremilast and IRA

The IRA’s drug price negotiations aim to lower costs but risk limiting patient access, treatment options, and future innovation. The SDPA urges policymakers to balance affordability with maintaining a broad range of therapies essential for individualized patient care.

Pharmacy Benefit Reform - New York S.1267-A

Pharmacy Benefit Reform Fails in 118th Congress New York S.1267-A Sets Precedent for States Moving Forward

SDPA Strengthens Advocacy and Public Relations Program with Key Leadership Appointments

SDPA Urges Action to Support Step-Therapy Reform Bill S.1267-A

Tell Congress to Recognize the High Quality of Care Delivered by PAs!

SDPA and other Healthcare Groups Applaud Filing of the Safe Step Act in the U.S House and Senate ​

SDPA Signs Letter Asking Congress to Include Medical Treatments in Mental Health Legislation

SDPA Joins Coalition to Support Lower Out-of-Pocket Patient Expenses

SDPA Board Sends Letter to Congress Encouraging Support of the Non-Profit Sector

The Society of Dermatology Physician Assistants (SDPA) urges Congress to also include associations, nonprofits and other tax-exempt organizations within any federal aid packages or supplemental appropriations measures.

News Categories